Bristol Myers Squibb Co. stock rises Friday, still underperforms market
The stock's fall snapped a two-day winning streak.
Companies sold a record $8 trillion of bonds last year amid high demand and lower borrowing costs
Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...
Hosted on MSN23h
Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma
Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...
Bristol-Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of unusually large options trading activity on Thursday. Stock investors acquired 296,826 call options on the company. This is an ...
MM&M2h
Big Pharma hikes prices of 250 drugs in January
Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.
nationthailand18h
Drugmakers raised prices on 250+ medicines in the US starting Jan. 1
Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
healthday6h
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subc ...
CAR-T Cell Therapy Market Research 2024-2025: Navigating the CAR-T Landscape, Major Players, Recent Approvals, and Pioneering Therapies
This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape.Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - ...
pharmaphorum23h
BMS adds to IBD pipeline with $1.9bn GentiBio deal
Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes an undisclosed ...
Will AI revolutionize drug development? Researchers explain why it depends on how it’s used
The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors and the general public. “Artificial intelligence ...